A Phase I Study to Assess the Safety and Tolerability of Pembrolizumab in Combination With Fixed Rate Gemcitabine Chemotherapy in Patients With Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma
Phase of Trial: Phase I/II
Latest Information Update: 13 Dec 2017
At a glance
- Drugs Gemcitabine (Primary) ; Pembrolizumab (Primary)
- Indications Leiomyosarcoma
- Focus Therapeutic Use
- Acronyms GEMMK
- 31 Aug 2018 Biomarkers information updated
- 08 Dec 2017 Planned End Date changed from 1 Jan 2019 to 1 Dec 2019.
- 08 Dec 2017 Planned primary completion date changed from 1 Jan 2019 to 1 Dec 2019.